<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46818">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01795027</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCCGPS</org_study_id>
    <secondary_id>ZHOUZHIWEI</secondary_id>
    <nct_id>NCT01795027</nct_id>
  </id_info>
  <brief_title>Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer</brief_title>
  <acronym>POTENT</acronym>
  <official_title>A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: It is shown that TS-1 as adjuvant chemotherapy after D2 resection in patients
      with gastric cancer can improve DFS and OS in one Japanese Trial. And TS-1 has become one of
      the standard  therapies  to these patients. But it is still unknown whether  it would
      improve more to OS and DFS than single TS-1 after combined with oxaliplatin . This trial is
      designed to investigate  the efficacy and safety  of  TS-1 plus oxaliplatin versus TS-1
      single as adjuvant chemotherapy after D2 resection in patients with gastric cancer.

      Patients and methods: In this study , patients with histologically confirmed gastric cancer
      who received D2 resection and staged II or III, aged from 18 to 70  years and  with Eastern
      Cooperative Oncology Group performance status â‰¤2 and adequate organ function, are randomized
      1:1 to oxaliplatin 100mg/m2 on day 1 and TS-1 40~60mg twice everyday for 14 days in a
      21-days cycle for total 6 cycles followed by TS-1  single with the same dose and frequency
      to the end of the 1st year postoperatively(SOX) , or  TS-1  single 40~60mg twice everyday
      for 14 days in a 21-days cycle to the end of the 1st year postoperatively (TS-1). The
      primary end point is overall survival (OS), and  secondary end point is disease free
      survival(DFS) and safety. Final study analysis will be conducted in the end of the 5th year
      after the last patient's enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>5 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>5 year after the last patients enrolled</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrence</measure>
    <time_frame>5 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>5 years after the last patient enroll</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">724</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>S-1 plus Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-1 single</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>S-1 40~60mg twice daily for 14 days in 3 weeks for totally 16 courses after D2 resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 plus oxaliplatin</intervention_name>
    <description>6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection</description>
    <arm_group_label>S-1 plus Oxaliplatin</arm_group_label>
    <other_name>SOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 single</intervention_name>
    <description>16 courses S-1 single after d D2 resection</description>
    <arm_group_label>S-1 single</arm_group_label>
    <other_name>S-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consensus of patients

          -  be able to receive oral administration

          -  from 18 to 70 years old

          -  be proven to be primary adenocarcinoma of gastric cancer and staged II or III by
             pathological evidences

          -  without other chemotherapy and/or radiation against to the disease

          -  normal function of other organs including heart,liver ,kidney and so on

          -  Eastern Cooperative Oncology Group performance status:0~2

        Exclusion Criteria:

          -  history of other malignancy

          -  allergic reaction to S-1 or oxaliplatin

          -  be enrolling in other clinical trials

          -  abnormal GI tract function

          -  dysfunction of other organs

          -  female in pregnancy or lactation,or refuse to receive Contraception measures during
             chemotherapy

          -  other situation to be judged not adaptive to the study by investigators
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiwei Zhou, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>SunYat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhiwei Zhou, PHD</last_name>
    <phone>86(020)87343626</phone>
    <email>zhouzhw@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuanfang Li, PHD</last_name>
    <phone>86(020)87343123</phone>
    <email>liyuanf@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the central hospital of Chaozhou</name>
      <address>
        <city>Chaozhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaoxiong Xie</last_name>
      <phone>13502633570</phone>
      <email>xzx60111@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the 1st people's hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Wang, ph.d</last_name>
      <phone>18666392971</phone>
      <email>wangwei@fsyyy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Traditional Medical Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Wan, ph.d</last_name>
      <phone>13602838202</phone>
      <email>reiqiwj@yahoo.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>cancer center of Sun yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhiwei zhou, PH. D</last_name>
      <phone>1390222289</phone>
      <email>zhouzhw@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>yuanfang li, PH. D</last_name>
      <phone>13503065940</phone>
      <email>liyuanf@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>the 6th affliated hospital of Sun-yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>junsheng peng, ph.d</last_name>
      <phone>13527618858</phone>
      <email>pengjunsheng@tom.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>cancer center of Guangzhou medical college</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiying Liu, ph.d</last_name>
      <phone>13725182319</phone>
      <email>gzdlhy@yahoo.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the 1St Affliated Hospital of Guangzhou Medical College</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Lei, ph.d</last_name>
      <phone>13903070123</phone>
      <email>drlei@21cn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the 1st affliated hospital of Guangdong pharmacuetic college</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weibin Zhang, ph.d</last_name>
      <phone>13002033388</phone>
      <email>zhangwb_0001@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the cental hospital of Shantou</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiyong Wu, ph.d</last_name>
      <phone>13502953050</phone>
      <email>stwuzy@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the 1st hospital of Shantou University</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Li, ph.d</last_name>
      <phone>13802716679</phone>
      <email>lwmail@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>YUE-BEI people's hospital</name>
      <address>
        <city>Shaoguan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Zhang</last_name>
      <phone>13500206389</phone>
      <email>ybyyzhangtao@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the 2nd people's hospital of Shenzhen</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Zheng, ph.d</last_name>
      <phone>13902489160</phone>
      <email>zkzk1212@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the 5th hospital of Sun-yat-sen University</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bingzong Hou, ph.d</last_name>
      <phone>13172660798</phone>
      <email>houbingzong@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 16, 2013</lastchanged_date>
  <firstreceived_date>February 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhou Zhiwei</investigator_full_name>
    <investigator_title>Director of Gastric and Pancreatic Surgery,cancer center of Sun Yat-sen U</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>D2 resection</keyword>
  <keyword>S-1</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
